



Attorney [REDACTED] Set No. 06171.105026 (IDX 1005 US)

16/23

#61A
9-11-02
Done

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Martin L. Bryant *et al.*

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
AUG 30 2002

Serial No.: 09/883,033

Filed: June 15, 2001

TECH CENTER 1600/2900

Title: 3'-Prodrugs of 2'-Deoxy- β -L-Nucleosides

Assistant Commissioner for Patents

Washington, DC 20231

August 16, 2002

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT


Sir:

In response to the Restriction Requirement mailed on July 16, 2002, please amend the above-identified application as follows.

In the Claims

Please cancel claims 1-155; 157-162 and 164-174. Please add claims 175-241 as follows:

175. (New) A compound of the formula:



or its pharmaceutically acceptable salt thereof, wherein

R^2 is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate prodrug; and



AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT
U.S.S.N. 09/883,033
Filed on June 15, 2001
Attorney Docket No. 06171.105026 (IDX 1005 US)

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8 (a)

I hereby certify that this Amendment and Response to Restriction Requirement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Josephine Young

Date: August 16, 2002